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ABSTRACT
Objectives: To explore changes in healthcare
professionals’ views about the diagnosis and
management of heart failure since a study in 2003.
Design: Focus groups and a national online cross-
sectional survey.
Setting and participants: Focus groups (n=8 with a
total of 56 participants) were conducted in the North
East of England using a phenomenological framework
and purposive sampling, informing a UK online survey
(n=514).
Results: 4 categories were identified as contributing
to variations in the diagnosis and management of heart
failure. Three previously known categories included:
uncertainty about clinical practice, the value of clinical
guidelines and tensions between individual and
organisational practice. A new category concerned
uncertainty about end-of-life care. Survey responses
found that confidence varied among professional
groups in diagnosing left ventricular systolic
dysfunction (LVSD): 95% of cardiologists, 93% of
general physicians, 66% of general practitioners (GPs)
and 32% of heart failure nurses. For heart failure with
preserved ejection fraction (HFpEF), confidence levels
were much lower: 58% of cardiologists, 43% of
general physicians, 7% of GPs and 6% of heart failure
nurses. Only 5–35% of respondents used natriuretic
peptides for LVSD or HFpEF. Confidence in interpreting
test findings was fundamental to the use of all
diagnostic tests. Clinical guidelines were reported to be
helpful when diagnosing LVSD by 33% of nurses and
50–56% of other groups, but fell to 5–28% for HFpEF.
Some GPs did not routinely initiate diuretics (23%),
ACE-inhibitors (22%) or β-blockers (38%) for LVSD for
reasons including historical teaching, perceived side
effects and burden of monitoring. For end-of-life care,
there was no consensus about responsibility for heart
failure management.
Conclusions: Reported differences in the way heart
failure is diagnosed and managed have changed little
in the past decade. Variable access to diagnostic tests,
modes of care delivery and non-uniform management
approaches persist. The current National Health Service
(NHS) context may not be conducive to addressing
these issues.
INTRODUCTION
Heart failure (HF) is a major health problem
in industrialised countries with ageing popu-
lations.1 HF diagnosis and management are
complex with variable care provision.2 Some
variability may relate to access to services,3
regardless of public or private provision.2 4
The key to reducing mortality, morbidity and
costs associated with HF is early, accurate
diagnosis and appropriate management.5–7
Traditionally, HF has been attributed to left
ventricular systolic dysfunction (LVSD), gen-
erally measured as a reduced ejection frac-
tion. The evidence base for treatment with
medication and device therapy relates to
LVSD,8 but over 50% of HF hospitalisations
occur in patients with preserved ejection
fraction (heart failure with preserved ejec-
tion fraction (HFpEF)).9–12 HFpEF has some-
times been equated with diastolic HF,
although the existence of HFpEF per se has
been questioned and an evidence base for
treatment is lacking.13 14 HF is difficult to
diagnose accurately as symptoms are often
non-specific and physical signs can be diffi-
cult to elicit15 16; there is evidence to suggest
that diagnosis is missed in up to two-thirds of
cases.17
Strengths and limitations of this study
▪ Focus groups were held with a wide range of
clinical staff to the point of data saturation and
validated against historical work.
▪ The questionnaire response rate was low,
although 514 professionals responded.
▪ Nevertheless, this study provides new under-
standing of the reasons behind the evidence-
practice mismatch for heart failure diagnosis and
management in the UK; in particular, the findings
highlight the difficulties faced by clinicians in
implementing current guidelines.
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In 2003, we reported reasons why general practitioners
(GPs) had not implemented best evidence in the diag-
nosis and management of HF.2 Key barriers included a
lack of confidence in diagnosis and management, a lack
of awareness of the relevant evidence base for care, and
variation in GPs’ personal preferences and organisa-
tional care pathways. Since then, there have been major
National Health Service (NHS) reorganisations includ-
ing dedicated HF services18 and the introduction of
technologies such as cardiac resynchronisation therapy
(CRT).19 Despite, or perhaps because of, ongoing devel-
opments, there is variability in the diagnosis and man-
agement of HF20 including service access,3 4 which
includes the availability and use of services. This two-
phase study evaluated key barriers and facilitators to the
appropriate management of HF in the UK, comparing
findings with those reported in 2003,2 and extending
the previous evaluation to include cardiologists, general
physicians and HF nurses as well as GPs in a national
survey. The previous study2 employed purely qualitative
methods (focus groups) with GPs in the North East of
England. The current (national) study sought to repli-
cate and expand this to include focus groups with GPs
and other relevant clinicians, and a national survey of
specialist and non-specialist clinicians.
METHODS
Focus group participants were recruited from health
authority registers for the North East of England, includ-
ing salaried GPs and GP partners, cardiologists, general
physicians and HF nurses. Purposive sampling21 allowed
a diverse representation of gender, role, seniority, ethni-
city, geographical distribution, employment status (part
or full time) and practice size (group or single-handed)
and avoided over-representation of individual practices.
Specific numbers were guided by data saturation across
groups.22 A qualitative (hermeneutic phenomeno-
logical) approach23 24 was used to explore clinicians’
decision-making, as well as experiences of barriers and
facilitators to delivering HF care. Thus, the emphasis was
on participants describing their experiences and beliefs
about ‘what can and should be done’. During focus
groups, a facilitator presented clinical vignettes covering
the diagnosis of LVSD and HFpEF, the use of B-type
natriuretic peptide and N-terminal pro-B-type natriuretic
peptide (BNP and NT-proBNP) and ECGs, the use of
ACE-inhibitors (ACEi), β-blockade and spironolactone
therapy, cardiac resynchronisation therapy, rehabilitation
and end-of-life care. Sessions were audio taped, tran-
scribed verbatim and verified by the facilitator (AF or
JJM) and moderator (HCH or HC).
Themes derived from the focus groups informed the
development of a UK survey which sought to assess views
about care provision from diagnosis to the end of life.
An initial pilot survey involved 14 healthcare profes-
sionals drawn from the groups of interest. Piloting pro-
moted a survey language and format that was acceptable
and meaningful to participants. The survey presented a
series of neutral multiple-choice and open questions
about the diagnosis and management of HF (LVSD and
HFpEF), as well as facilitators and barriers to care (the
survey can be viewed here: https://www.survey.bris.ac.
uk/durham/hf_survey). The survey was anonymised by
code and an invitation to participate was sent by email
to the complete sample of each of the five professional
groups held by Binley’s (http://www.binleys.com/); to
maximise response, a reminder email was sent after
3 weeks. Binley’s hold healthcare and public sector data,
mailing lists, directories and maps covering NHS and
local government; figures indicate that they hold contact
details for 16 442 staff in the relevant groups (compris-
ing: 2619 for cardiology and general medicine, 319 for
specialist nurses and 13 504 for salaried GPs and GP
partners). We estimated that a sample size of about 2100
would permit population rate precisions for binary
values of about 2% (eg, rate 25%, deviation 2%, confi-
dence 95%, N=1798). Subgroup sizes would permit dif-
ferences between groups of about 10% (eg, 20% vs 30%,
90% power, 5% α, N=412 per group, Fisher’s exact test).
Data analysis
Thematic data analysis23 24 conducted by two phenom-
enologists (HCH and HC) produced a textural descrip-
tion of experiences of diagnostic and care provision for
HF from the focus groups25; neither analyst was involved
in the 2003 study. Preliminary codes were identified by
each analyst, refined as coding progressed, and grouped
into categories. From these, a set of themes emerged
which were tested using diverse accounts within and
between cases to challenge and define the integrity of
the theme boundaries. Findings were subsequently dis-
cussed by the whole team.
Descriptive data analysis, using SPSS V.19, was used to
summarise survey findings and explore subgroup pat-
terns. The key subgroups were salaried (permanent,
locum and out-of-hours) GPs, GP partners, cardiologists,
general physicians and HF nurses. A lower than
expected response rate was achieved and prevented a
meaningful analysis of differences between groups.
Results
Study population
Eight focus groups with salaried and partner GPs, cardi-
ologists, general physicians and HF nurse participants
(39 GPs, 4 cardiologists, 6 general physicians and 7 HF
nurses) were conducted between December 2010 and
March 2011 in affluent and deprived locations in the
North East of England.
For the national survey, of eligible staff from the pro-
fessional groups included, 514 (3.1%) responses were
received from staff working in 40 strategic health author-
ities (SHAs) across the UK. Of these, 10 were duplicate
responses and a further 10 declined to indicate their
occupational group; thus, a total of 494 unique
responses were included in the analysis. Reasons for
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non-participation are unknown. Not all respondents
answered all questions; thus, denominators for each
group and question are tabulated.
The majority of survey participants (69.4%) were aged
between 41 and 60 years of age, were male (54.5%) and
worked within an English SHA (85.3%). Baseline
characteristics of participants are shown in table 1.
Similar demographic trends were apparent in each pro-
fessional group with the exception of salaried GPs and
nurses who were predominantly female. Focus group
themes and survey responses are reported together.
Study findings
From the focus groups, four categories were identified
which contribute to variations in the diagnosis and man-
agement of HF: uncertainty about clinical practice, the
value of clinical guidelines, tensions between individual
and organisational practice, and, uncertainty about
end-of-life care. The first three categories virtually repli-
cated 20032 findings, and the fourth was new.
The diagnostic process
The majority of survey respondents had responsibility
for diagnosing HF due to LVSD with the exception of
nurses of whom 23% reported doing so. Comorbidities
and non-specific symptoms and signs were the most chal-
lenging aspect of making a diagnosis. Cardiologists,
general physicians and nurses rated comorbidities
highest while GPs rated non-specific signs and symptoms
as most highly challenging. A lower proportion of HF
nurses (32%) were confident in their ability to diagnose
LVSD than any other group, followed by GPs (66%)
when compared with 95% and 92% of cardiologists and
general physicians.
I’d leave it to specialists (Out-of-hours GP)
The majority of cardiologists (87%) identified that
they had responsibility for diagnosing HFpEF, followed
by general physicians (59%). Of the 13 cardiologists
who did not diagnose HFpEF, 9 were not convinced that
HFpEF exists. Most GPs (84%) and nurses (87%) did
not diagnose HFpEF. A lower proportion of GPs (7%)
were more confident in their ability to diagnose HFpEF
than any other group. One cardiologist commented that
they would like access to “A crystal ball” to inform
HFpEF diagnosis, while a GP partner asked “What is
HFpEF?”
A cardiologist highlighted the complex nature of
diagnosis:
I’ve rescued a few people with heart failure from asthma
clinics…But we all know it’s very hard to do sometimes,
isn’t it, in someone who’s breathless and they’ve got
crackles and they’ve got a funny looking x-ray, and distin-
guishing between fibrosis and chronic lung disease and
heart failure, just on that first visit isn’t always very easy.
(Cardiologist)
Diagnostic tests
The majority of survey respondents who diagnosed
LVSD used ECGs, chest X-rays and clinical assessment,
the exception being nurses. Around a quarter of the
nurses (23%) and half of the GPs (49%) were confident
in interpreting the results of an ECG while most cardiol-
ogists and general physicians (both: 87%) were confi-
dent. One-third of nurses (33%) and two-thirds of GPs
(65%) were confident in interpreting the results of an
echocardiogram while the majority of cardiologists and
general physicians (98% and 85%, respectively) were
confident. Cardiologists were more likely to use ECGs
and chest X-rays (64% and 63%, respectively) to diag-
nose HFpEF than other groups; clinical assessment was
almost never used by any group. This was reflected in
the confidence levels in interpreting these results (see
table 2).
Availability and use of echocardiography services
For LVSD, echocardiographic findings were used by
97% of cardiologists, 91% of general physicians, 52% of
salaried GPs, 35% of GP partners and 31% of nurses.
Even though availability was generally high, some GPs
and general physicians were reluctant to use open access
echocardiography because of a lack of knowledge about
interpreting results; many preferred to refer the patient
to a cardiologist or to a specialist HF clinic.
…I don’t understand a lot of the [echocardiograms]…
(GP partner)
Table 1 Baseline characteristics of survey respondents
Characteristics Participants
Age (years)*
20–40 125 (26%)
41–60 333 (69%)
61+ 22 (5%)
Gender†
Male 263 (55%)
Female 220 (45%)
UK region‡
England 422 (85%)
Scotland 24 (5%)
Wales 32 (7%)
Northern Ireland 12 (2%)
Professional group§
Salaried GP 84 (17%)
Partner GP 167 (33%)
Cardiologist 103 (20%)
General physician 54 (11%)
Heart failure nurse 78 (16%)
Other 8 (2%)
Denominator for each variable:
*n=480.
†n=483.
‡n=490.
§n=494.
GP, general practitioner.
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Cardiologists and nurses were more confident in using
and interpreting echocardiography reports than GPs but
expressed frustration about patients not routinely
referred for echocardiography testing and the poor
quality of referral information:
…we go onto the ward, we read the notes, and it’s
screaming heart failure at you, screaming it. And
nobody’s considered doing an echo. And…you want to
just say, will you please echo this patient! (HF nurse)
To diagnose HFpEF, most cardiologists used echocar-
diography (91%) followed by physicians (67%), salaried
GPs (30%), nurses (21%) and GP partners (17%).
Again, confidence in using results reflected this pattern
of usage (table 2).
Availability and use of BNP and NT-proBNP
GPs were more likely to use BNP (28%) than other
groups; similarly, NT-proBNP was used in low propor-
tions. Between 10% and 50% of all respondents
expressed a need for access to natriuretic peptides.
However, a general physician commented:
We have tried BNP and found that it added no value
(General Physician).
Table 2 Beliefs about current practice, facilitators and barriers to the diagnosis of LVSD and HFpEF
Diagnostic issue
GP Cardiologist General physician HF nurse Total
N=251 N=103 N=54 N=78 N=494
Currently diagnose
LVSD 189 (75.3%) 99 (96.1%) 51 (94.4%) 18 (23.1%) 357 (72.3%)
HFpEF 40 (15.9%) 90 (87.4%) 32 (59.3%) 10 (12.8%) 172 (34.8%)
Confident to diagnose
LVSD 166 (66.1%) 98 (95.1%) 50 (92.6%) 25 (32.1%) 339 (68.6%)
HFpEF 17 (6.8%) 60 (58.3%) 23 (42.6%) 5 (6.4%) 105 (21.3%)
Use echocardiography to diagnose
LVSD 103 (41%) 100 (97.1%) 49 (90.7%) 24 (30.8%) 276 (55.9%)
HFpEF 54 (21.5%) 94 (91.3%) 36 (66.7%) 16 (20.5%) 200 (40.5%)
Would use echo but no access for
LVSD 4 (1.6%) 0 (0%) 1 (1.9%) 0 (0%) 5 (1%)
HFpEF 7 (2.8%) 1 (1%) 2 (3.7%) 0 (0%) 10 (2%)
Use BNP to diagnose
LSVD 69 (27.5%) 16 (15.5%) 7 (13.0%) 7 (9.0%) 99 (20.0%)
HFpEF 23 (9.2%) 19 (18.4%) 10 (18.5%) 2 (2.6%) 54 (10.9%)
Would use BNP but no access for
LVSD 82 (32.7%) 24 (23.3%) 27 (50.0%) 8 (10.3%) 141 (28.5%)
HFpEF 30 (12.0%) 22 (21.4%) 19 (35.2%) 4 (5.1%) 75 (15.2%)
Use NT-proBNP to diagnose
LSVD 45 (17.9%) 26 (25.2%) 6 (11.1%) 6 (7.7%) 83 (16.8%)
HFpEF 14 (5.6%) 25 (24.3%) 4 (7.4%) 4 (5.1%) 47 (9.5%)
Would use NT-proBNP but no access for
LVSD 57 (22.7%) 30 (29.1%) 17 (31.5%) 9 (11.5%) 113 (22.9%)
HFpEF 20 (8.0%) 26 (25.2%) 10 (18.5%) 5 (6.4%) 61 (12.3%)
Use ECGs to diagnose
LVSD 172 (68.5%) 84 (81.6%) 40 (74.1%) 15 (19.2%) 311 (63.0%)
HFpEF 43 (17.1%) 66 (64.1%) 27 (50.0%) 12 (15.4%) 148 (30.0%)
Would use ECGs but no access for
LVSD 1 (0.4%) 0 (0%) 0 (0%) 1 (1.3%) 2 (0.4%)
HFpEF 2 (0.8%) 0 (0%) 1 (1.9%) 0 (0%) 3 (0.6%)
Use chest X-rays to diagnose
LVSD 156 (62.2%) 67 (65.0%) 42 (77.8%) 9 (11.5%) 274 (55.5%)
HFpEF 44 (17.5%) 65 (63.1%) 28 (51.9%) 6 (7.7%) 143 (28.9%)
Would use chest X-rays but no access for
LVSD 3 (1.2%) 0 (0%) 0 (0%) 0 (0%) 3 (0.6%)
HFpEF 5 (2.0%) 0 (0%) 1 (1.9%) 0 (0%) 6 (1.2%)
Use clinical assessment to diagnose
LVSD 200 (79.7%) 92 (89.3%) 49 (90.7%) 21 (26.9%) 362 (73.3%)
HFpEF 1 (0.4%) 3 (2.9%) 1 (1.3%) 0 (0%) 5 (1.0%)
BNP, B-type natriuretic peptide; GP, general practitioner; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; LVSD, left
ventricular systolic dysfunction; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
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Between 10% and 61% of all respondents expressed
confidence in interpreting the results of natriuretic pep-
tides in LVSD diagnosis (table 2). Few practitioners use
natriuretic peptides to diagnose HFpEF.
Communicating a diagnosis
All cardiologists (100%) and most physicians (94%) and
nurses (95%) took responsibility for informing patients
of a HF diagnosis; a minority of GPs felt that this was
not their responsibility (16%) but a cardiologist’s. One
cardiologist commented:
In some patients it is very easy and in some very difficult.
Communicating difficult information well requires train-
ing and experience. (Cardiologist)
And another:
I think it’s something we haven’t been trained to do.
(Cardiologist)
Most participants felt it was important to educate
patients about their illness but some expressed concerns
about informing patients of their diagnosis as this might
lead to anxiety.
I don’t tend to tell them that their prognosis is pretty
lousy if they’ve got a bad heart, which it is, isn’t it.
(Cardiologist)
The value of clinical guidelines
When diagnosing LVSD, a third of nurses (33%) and
about a half (50–56%) of other groups found clinical
guidelines helpful (table 3). All groups identified the
National Institute for Health and Care Excellence
(NICE) guidelines as the most helpful for the manage-
ment of LVSD (50–89%). Information overload was seen
as a common cause of anxiety among salaried and part-
nered GPs. Some participants felt that it was ‘too late’
for them to be educated.
The problem with being a GP is there’s so many; if you
read all of the bloody NICE guidelines that were relevant
to us, and there’re all big weighty documents, and we’re
meant to all look at them, and sign them off for the PCT.
(GP partner)
I mean things like pacing and ventricular pacing and syn-
chronised pacing. Those are things which are way beyond
me, I say, it’s too late for me to be educated in that. I like
the heart failure team to make that decision. (General
physician)
When managing LVSD, nearly all nurses (95%) and
the majority of other groups (57–73%) found clinical
guidelines helpful. All groups identified NICE guidelines
as the most helpful (53–80%). A GP partner stated:
…guidelines rarely cover options in poly-pharmacy and
are written by academics. (GP Partner)
Only a minority of respondents in any group found clinical
guidelines helpful when diagnosing and managing HFpEF.
Some GPs and HF nurses felt duty bound to follow
guidelines but expressed frustration that they did not
offer enough scope for individualised care:
I try and use them but I think a lot of people don’t fit
into them, the little boxes. (GP partner)
Some salaried and locum GPs valued guidelines and
expressed the view that they led to more confident
decision-making:
…it gives you confidence if you’ve got some guidelines,
sitting with the patient, you can follow, you know, follow
instructions a little bit, which does make you feel a bit
more confident. (Locum GP)
In contrast, cardiologists appeared more confident in
using their clinical judgement and discretion in preference
to following guidelines and described decision-making in
more complex, multilevel and nuanced ways than GPs.
…trying to keep abreast of what the literature’s suggest-
ing you do, but also the fact that you’re a little bit con-
strained by guidelines that are seemingly quite behind
the literature. (Cardiologist)
HF management
Of those who managed LVSD, all groups cited
comorbidities as the most challenging aspect of manage-
ment. GPs and general physicians cited polypharmacy
as being the second most challenging aspect, while
cardiologists and nurses cited unpredictable disease pro-
gression. Some GPs felt that the organisation of care,
with an emphasis on specialist HF services, led to deskill-
ing in primary care.
The thing that concerns me most is being deskilled
because as I’m doing much less management of heart
failure than, the heart failure nurses are probably doing
a lot more. (GP Partner)
A particular concern among GPs, regardless of the
level of experience, was anxiety about the delicate risk–
benefit balance where management required
investigations, initiation and titration of evidence-based
medication and monitoring:
Things like titrating the beta blockers as well, and ACE
inhibitors, diuretics. It’s all a challenge really. (Salaried
GP)
And the other thing, it’s a necessary evil, all the monitor-
ing you have to do when you’re titrating the medications.
You just have to see people every bloody two weeks. (GP
partner)
Cardiologists most commonly initiated medication for
the treatment of LVSD, although the majority of all
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groups reported initiating medication (table 4). Some
GPs did not routinely initiate diuretics (23%), ACEi
(22%) or β-blockers (38%). All respondents reported
titrating medication for the treatment of LVSD.
Concerns surrounding the initiation and titration of
ACEi and β-blockers seemed to arise as a result of previ-
ous teaching, a fear of side effects and the burden of
monitoring.
The danger of impaired renal function with high doses
of not only the diuretics but the ACE inhibitors as well
juggling doses of ACE inhibitors against diuretics, up and
down, checking potassium. I do find some of those con-
flicts difficult to resolve. (GP partner)
There was a reluctance to prescribe additional medica-
tions to a group characterised by polypharmacy and
comorbidities; this was seen as a particular problem in
the elderly:
Particularly in more frail/elderly people for example,
particularly if the blood pressure is hovering around
100–110 anyway, because of their age and you crank their
ACE inhibitor as far as it can go, maybe a little bit dry as
well, I think a β-blocker on top of that is always a bit of a
concern. Relatively easy to do, maybe, when the patient’s
already in hospital, and is going to be in for another day
or so and they can see probably what’s going to happen
but it’s more difficult out in the community. (GP
partner)
All professional groups shared a reluctance to increase
dosage if the patient was asymptomatic or stable:
I must say I’m inclined to do it when the patient’s strug-
gling a wee bit rather than when they’re well. You know if
you’ve got a perfectly, someone who’s feeling great, and
you put them on an ACE inhibitor and their kidney goes
pear shaped, I tend to just not do anything I must admit.
(Cardiologist)
Most GPs admitted to being unaware of the place for
other agents including spironolactone and angiotensin
II antagonists in treating HF:
What I’m not clear about is spironolactone, do we adjust
the dose of that? It seems 25 mg is the recommended
dose and yet when we used to use it 30 odd years ago it
was always 100 mg of spironolactone. Is it more danger-
ous to use a higher dose, is there a titration schedule? I
don’t know. (GP partner)
Table 3 Beliefs about the use of clinical guidelines in the diagnosis and management of HF
Management issue
GP Cardiologist General physician HF nurse All respondents
N=251 N=103 N=54 N=78 N=494
Helpful for diagnosing LVSD 139 (55.4%) 58 (56.3%) 27 (50.0%) 26 (33.3%) 250 (50.6%)
Helpful for diagnosing HFpEF 28 (11.2%) 29 (28.2%) 15 (27.8%) 4 (5.1%) 76 (15.4%)
Helpful for managing LVSD 166 (66.1%) 75 (72.8%) 31 (57.4%) 74 (94.9%) 346 (70.0%)
Helpful for managing HFpEF 33 (13.1%) 28 (27.2%) 15 (27.8%) 14 (17.9%) 90 (18.2%)
GP, general practitioner; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; LVSD, left ventricular systolic dysfunction.
Table 4 Beliefs about current practice, facilitators and barriers to the pharmaceutical management of LVSD and HFpEF
Management issue
GP Cardiologist General physician HF nurse All respondents
N=251 N=103 N=54 N=78 N=494
Role in management of LVSD 203 (80.9%) 100 (97.1%) 44 (81.5%) 74 (94.9%) 421 (85.2%)
Role in management of HFpEF 69 (27.5%) 87 (84.5%) 29 (53.7%) 51 (65.4%) 236 (47.8%)
Initiate medication for LVSD 202 (80.5%) 102 (99.0%) 50 (92.6%) 73 (93.6%) 427 (86.4%)
Titrate medication for LVSD 225 (89.6%) 101 (98.1%) 50 (92.6%) 77 (98.7%) 453 (91.7%)
Initiate diuretics for LVSD 193 (76.9%) 97 (94.2%) 46 (85.2%) 70 (89.7%) 406 (82.2%)
Titrate diuretics for LVSD 165 (65.7%) 61 (59.2%) 30 (55.6%) 70 (89.7%) 326 (66.0%)
Initiate ACEi for LVSD 196 (78.1%) 101 (98.1%) 49 (90.7%) 71 (91.0%) 417 (84.4%)
Titrate ACEi for LVSD 204 (81.3%) 92 (89.3%) 33 (61.1%) 76 (97.4%) 405 (82.0%)
Initiate ARB for LVSD 128 (51.0%) 80 (77.7%) 21 (38.9%) 64 (82.1%) 293 (59.3%)
Titrate ARB for LVSD 113 (45.0%) 65 (63.1%) 11 (20.4%) 73 (93.6%) 262 (53.0%)
Initiate β-blockers for LVSD 155 (61.8%) 101 (98.1%) 41 (75.9%) 69 (88.5%) 366 (74.1%)
Titrate β-blockers for LVSD 181 (72.1%) 91 (88.3%) 30 (55.6%) 76 (97.4%) 378 (76.5%)
Initiate spironolactone for LVSD 95 (37.8%) 98 (95.1%) 40 (74.1%) 67 (85.9%) 300 (60.7%)
Titrate spironolactone for LVSD 79 (31.5%) 48 (46.6%) 19 (35.2%) 63 (80.8%) 209 (42.3%)
Initiate digoxin for LVSD 55 (21.9%) 63 (61.2%) 24 (44.4%) 41 (52.6%) 183 (37.0%)
Titrate digoxin for LVSD 47 (18.7%) 29 (28.2%) 10 (18.5%) 39 (50.0%) 125 (25.3%)
ACEi, ACE-inhibition; ARB, angiotensin receptor blockers; GP, general practitioner; HF, heart failure; HFpEF, heart failure with preserved
ejection fraction; LVSD, left ventricular systolic dysfunction.
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Several respondents reflected on the lack of effective
symptomatic treatment for HFpEF, leading to “an inabil-
ity to do anything useful” (GP partner), while another
GP partner stated:
I remember when I was doing my medical training, actu-
ally on a hospital basis, it (HFpEF) was semi-mythical
and… it was apparently very difficult to diagnose and no
one was quite sure what medications were best for it. So
it was just assumed that everybody had systolic heart
failure or cor pulmonale and then there were a few odd
people who might have diastolic, we didn’t know what to
do about them. Well I still don’t know what to do about
them. (GP Partner)
A nurse stated:
I’m not comfortable in titrating people with that diagno-
sis (HFpEF) because there’s very little evidence out there
to say what drugs we should be using.
Non-pharmaceutical management of HF
Around half of the respondents in all groups reported
that they had access to rehabilitation for HF (table 5).
HF nurses and cardiologists highlighted the importance
of rehabilitation and frustration at the limitations on
service provision in this area.
We had a support group running for our patients for
about 4 years successfully, and now the commissioners
have just pulled it because they won’t fund it anymore. It
was an exercise support group, rehab, and they won’t
fund it now, so we can’t run it. (HF Nurse)
It’s patients who’ve had heart failure and previous coron-
ary disease…patients with heart failure secondary to car-
diomyopathy. Then it’s sometimes difficult to find a
rehab program for them. (Cardiologist)
Few GPs (18%) understood the indications for elec-
trical therapies in the management of HF compared
with nearly all cardiologists (98%).
…you think ‘crikey’, particularly with the younger heart
failure patients maybe they ought to go and talk to some-
body who knows a bit more than me. Because maybe
there are things that can be done for them that I
wouldn’t even dream about. (GP Partner)
Priorities for care in HF management
Views varied about priorities for investment to improve HF
services. Cardiologists, general physicians, salaried GPs
and nurses emphasised improved access to HF clinics and
HF nursing teams; salaried GPs cited education for GPs.
If you look at heart failure admissions since we intro-
duced specialist heart failure nurses and the heart failure
clinic in 2002, they’ve actually gone down year on year.
(General Physician)
…the clinic is every two weeks, so if you do the echo and
then a clinic, that’s 4 weeks you know, and 4 weeks
without β-blockers, 4 weeks perhaps without ACE inhibi-
tors…certainly we are dragging the whole process out.
(GP partner)
Tensions between individual and organisational practice
In addition to specialist medical training (or lack
thereof) and clinical experience, another important
theme influencing clinicians’ diagnosing behaviour
arose from the provisions made by outside organisations
(health authorities, secondary care trusts and primary
care trusts). For example, cardiologists and general phy-
sicians expressed concern about the organisation of spe-
cialist care by primary care trusts, which meant that
services were unavailable at weekends:
The worst is the weekends because on the weekends you
send a request out, this is logistics, it’s nothing to do with
the individual, because by the time they get the referral
it’s Tuesday, and you want the patient to be out by that
time. (General Physician)
Time constraints and generally increasing clinical and
administrative workload were highlighted by all GPs as
being a barrier to effective HF management:
To look after patients properly they are very time con-
suming consultations, they take a large portion of GPs
time…and the number of regular reviews that are clearly
needed to manage the patients properly. There aren’t
that many conditions that we treat with that degree of
Table 5 Beliefs about current practice, facilitators and barriers to the non-pharmaceutical management of LVSD and HFpEF
(selected questions)
Management issue
GP Cardiologist General physician HF nurse All respondents
N=251 N=103 N=54 N=78 N=494
Access to an HF clinic 150 (59.8%) 83 (80.6%) 36 (66.7%) 69 (88.5%) 338 (68.4%)
Routinely refer to an HF clinic 103 (41.0%) 65 (63.1%) 35 (64.8%) 66 (84.5%) 269 (54.5%)
Access to HF rehabilitation 126 (50.2%) 63 (61.2%) 24 (44.4%) 57 (73.1%) 270 (54.7%)
Access to electrical therapies for HF 172 (68.5%) 103 (100%) 42 (77.8%) 78 (100%) 395 (80.0%)
Access to end-of-life care pathway for HF 181 (72.1%) 84 (81.6%) 31 (57.4%) 69 (88.5%) 365 (73.9%)
Responsible for end-of-life care for HF 194 (77.3%) 35 (34.0%) 17 (31.5%) 61 (78.2%) 307 (62.1%)
GP, general practitioner; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; LVSD, left ventricular systolic dysfunction.
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intensity or regular review I don’t think. Perhaps cancer
care in the later stages. So a lot of doctor time. (GP
partner)
The majority of respondents in all groups had access
to a dedicated HF clinic provided by a multidisciplinary
team, though not all routinely referred patients to this
service. One GP partner stated: “…the mammoth wait
makes using this service impractical” while a cardiologist
commented “…selected patients are referred according
to where they live—patients are not referred routinely.”
All groups referred to the lack of integrated systems of
care, disease registers and compatible computer systems
across primary and secondary care as a barrier to com-
munication in HF care.
My major frustration is regarding patients who have
recurrent admissions with heart failure. And the frustra-
tion there basically is that I feel that there’s no joined up
care for these patients to be followed up by a professional
with an interest in heart failure, whether that is a primary
care physician with an interest in heart failure or a sec-
ondary care cardiologist with an interest in heart failure.
(General Physician)
…even trying to get blood results if you titrate the medi-
cation and you take bloods, getting the results I have to
ask the GPs to fax the results back to me. If we were
linked to the same system as the hospital, well even if
we’re on System One then we could get it. (HF nurse)
Uncertainty about end-of-life care
Most respondents stated that their patients had access to
an end-of-life pathway for HF, although these were used
only occasionally by any group other than nurses, 45%
of whom stated that they used care pathways frequently.
Most cardiologists and general physicians did not see
themselves as being responsible for end-of-life care for
HF, while around 80% of GPs and nurses felt that they
had responsibility within a team. There was a lack of
consensus about who held final responsibility for
end-of-life care, with most respondents identifying some
or all members of the multidisciplinary team as being
responsible.
Within most of the professional groups studied, ‘defin-
ing end-of-life’ was the most challenging aspect of
end-of-life care; ‘coordination of care’ was the second
most challenging aspect. A cardiologist stated that the
most challenging aspect was:
persuading overzealous colleagues that palliation is
appropriate.”
Another cardiologist highlighted the:
sometimes false expectations of patients and their fam-
ilies—sometimes fuelled by other health care profes-
sionals—sometimes fuelled by success of previous
treatment for heart failure. (Cardiologist)
The majority of participants, regardless of role, identi-
fied doubts about their ability to identify the end-of-life
stage and expressed fear about withdrawing active treat-
ment. Participants expressed frustration at trying to
balance the competing requirements of palliative plan-
ning, against a cultural emphasis on the use of invasive
technologies for end-stage HF. A cardiologist stated:
I have this overwhelming feeling that we’re almost sort of
being encouraged to put ICDs (Implantable Cardioverter
Defibrillators) into everybody. (Cardiologist)
Some GPs reported improvements in the care of
patients towards the end of life as a result of the intro-
duction of new care pathways, and the willingness of pal-
liative care service providers to treat patients with
non-cancer diagnoses:
We recently had a couple of heart failure patients go
through palliative care, end of life pathways, and it’s been
absolutely fantastic, the hospice and Macmillan, whatever,
and I think it’s a really new string to our bow, and a
really sophisticated sensible thing to have as well. (GP
Partner)
There was some acknowledgement that these pathways
could only be implemented for a minority of HF
patients. The remainder had difficulties in identifying
and communicating the end-of-life stage to patients and
their families, partly because of the unpredictable
nature of the disease progression.
From not knowing how long people have got left and
sort of declining and you don’t know whether it’s weeks
or months, do you, it’s very difficult to know at what
point, how quickly they’re going to go down. (Salaried
GP)
So it can be difficult sometimes I think, to broach it with
the patient, broach it with the carer, decide within a
team and then the issue of out of hours, sometimes you
decide this is it, and then you find that they’re admitted
to hospital overnight. (GP Partner)
Discussion
Among the five health professional groups studied, vari-
able opinions and practices persist in the diagnosis and
management of HF. Uncertainty about appropriate clin-
ical practice (including the diagnostic process and
medical management), utility of clinical guidelines and
individual practice preferences with local organisational
influences were similar to themes identified a decade
ago.2 Uncertainties around end-of-life care emerged as a
new theme.
The difficulty of achieving an accurate diagnosis of HF
has changed little in the past 10 years despite improved
access to diagnostics including natriuretic peptides and
echocardiography. Non-specific symptoms and signs,
and significant comorbidities in increasingly elderly
patients, continue to contribute to the complexity of
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diagnosis. Despite NICE guidance recommending natri-
uretic peptide testing when diagnosing HF, availability
and use remains variable. Although the vast majority of
survey respondents now have open access echocardiog-
raphy, NICE guidelines now discourage this and suggest
referral for specialist assessment for diagnosis and man-
agement.26 Comments from focus group respondents
highlighted the lack of awareness among some clinicians
about the existence or content of relevant guidelines.
Thus, it is possible to suggest that while the guidelines
themselves may have utility, variations in perceptions
and awareness of their content may have been a barrier
to optimum care.
A lack of knowledge about diagnosis and management
of HFpEF was evident across all professional groups,
including many cardiologists. Issues around communi-
cating the diagnosis of HF to patients and carers were
highlighted. Generally, the lack of an evidence base for
diagnosis and management of HFpEF meant that the
guidelines for this condition were deemed to be less
useful than those for LVSD. Of note was the fact that 9%
of cardiologists remained unconvinced about the exist-
ence of HFpEF, which may have influenced the confi-
dence of other clinicians when considering a diagnosis
of HFpEF.
Despite a decade of availability and clear guidance,
clinicians still vocalise concerns about initiating
β-blockers or digoxin, although survey findings suggest
that most clinicians initiate and titrate evidence-based
drugs for HF. The previous study identified ageism as a
potential source of variability, although in this study
ageism per se was not seen as a problem; rather, the
comorbidities associated with age.
Availability of diagnostics (including natriuretic pep-
tides), access to HF specialist services and rehabilitation
were variable and thus subject to geographical locality.
Cardiologists felt that lack of continuity of care and
service availability at weekends increased hospital admis-
sions and delayed hospital discharge. Lack of integrated
disease registers and joined up computer systems across
primary and secondary care were seen as a barrier to
communication in HF care.
In the previous study,2 participants were given the
opportunity during each focus group to identify and
discuss any sources of variation or difficulty in diagnos-
ing and managing HF. End-of-life care for HF was not
identified during these focus groups, perhaps reflecting
a lack of focus on this issue within the NHS. In the
current study, end-of-life was a preagreed topic for dis-
cussion but most participants highlighted the issue
without prompting from the facilitator, thus demonstrat-
ing its increasing relevance and importance to clinicians
today. Many participants felt that the main barrier to a
coordinated end-of-life management plan was the inabil-
ity to predict when the palliative phase should start in
patients with HF. There was a difficult balance to strike
between increasingly invasive technologies (including
CRT and International Classification of Diseases (ICD))
and palliative care planning underpinned by quality of
life considerations. All groups highlighted the difficulty
in communicating the end-of-life phase to patients and
carers, especially if high expectations for survival had
been raised by colleagues.
There appeared to be a lack of consensus about who
is responsible for HF care, from diagnosis through man-
agement to palliative care. This is despite the fact that
NICE guidelines recommend specialist care by multidis-
ciplinary HF teams for patients with suspected HF and
in patients with HF. Potential solutions to the difficulties
highlighted by this paper lie in improved service avail-
ability, access, coordination of care and education.
Previous national and international research has demon-
strated the value of a coordinated, multidisciplinary
approach to care in reducing hospital admissions, redu-
cing treatment variability and improving quality of life
for people with HF.27–30 Thus, specialist HF clinics are
available in many centres across the UK. However, these
services may not provide end-of-life care or address
some of the other issues raised by this study, such as the
education needs of GPs. One innovative solution to the
variability of HF care, recently implemented by study
team members, demonstrated the acceptability and feasi-
bility of an on-site specialist HF service for people in UK
care homes.31–34 Other research has evaluated
cardiology-palliative care teams, demonstrating their
potential to address some of the uncertainty around
care for these patients.35 Given the ageing population
and the increasing burden of HF, implementing more
innovative solutions is key to addressing the challenges
of HF care.
Strengths and limitations of the study
The mixed methods approach used in this study permit-
ted the key themes and issues experienced by clinicians
to be identified and a questionnaire to be developed to
quantify current beliefs and behaviours. Focus groups
were conducted to the point of data saturation and can
be validated to some extent against historical work,
although it would be useful for independent research to
confirm these themes. The response rate to the ques-
tionnaire appears low at 3.1%; however, this was an elec-
tronic survey with a substantial total number of
responses. Electronic surveys, as unsolicited emails, typic-
ally feature low responses. This style of technology has
been commonly used in market surveys and in clinical
and epidemiological research. Despite their relative
popularity and ease, they frequently do not reach all
patients. Qualitative and survey research, by necessity,
reports what respondents wish to say, which may differ
in some circumstances from their actual behaviour.36 37
It is possible that the respondents agreed to participate
in the survey as a result of shared frustration with the
issues raised, and that the findings are not representative
of the current clinical view. Although bias as a result of
self-selection is a possibility, findings from this research
mirror themes from other research nationally and
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internationally, suggesting that the challenges and pro-
blems are universal. Thus, this study provides further
understanding of the reasons behind the evidence-
practice mismatch for HF in the UK.
Conclusions
The reported reasons for variability in HF diagnosis and
management have changed little in the past decade.
Issues of service availability, access, delivery of care and a
lack of coordination persist. The current working envir-
onment appears not to be conducive to promoting own-
ership or engagement with such difficulties. Rather than
interventions targeted at clinicians to improve care, the
primary need may be for a health service, which enables
coordinated care, responsibility and training.
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